Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes

Abstract

BackgroundTeneligliptin is a novel, highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor. The aim of this study is to explore the glycemic and non-glycemic efficacies of teneligliptin as an initial therapy.MethodsNewly diagnosed, drug naive Japanese subjects with type 2 diabetes (T2DM) were assigned to 20 mg/day teneligliptin monotherapy (n = 31). At 3 months, levels of glycemic and other parameters were compared with those at baseline.ResultsSignificant reductions of HbA1c (from 10.34 ± 2.06 to 8.38 ± 2.23%) and fasting blood glucose (FGB, from 211.3 ± 68.4 to 167.3 ± 70.2 mg/dL) levels were observed without any clinically significant adverse events. However, significant increases of uric acids (UA) levels were observed and two subjects reported mild hypoglycemic events. Homeostasis model assessment-B (HOMA-B) levels significantly increased, while high HOMA-R levels significantly decreased. Significant correlations were observed between the changes (Δ) of HbA1c and those of HOMA-B, and between ΔFBG and ΔHOMA-R. No changes in lipid and body weight were noted.ConclusionsTeneligliptin might be effectively and safely used as an initial therapy for newly diagnosed T2DM. Glycemic efficacy of teneligliptin is obtained through activating beta-cell function as well as decreasing insulin resistance.

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)

“…Teneligliptin is a novel DPP-4 inhibitor, having a unique chemical structure which is characterized by five consecutive rings (J-shaped), which might account for its unique potency and half-life time 5,6. Teneligliptin was introduced in India in May 2015 and is available at almost one quarter to one fifth of the cost of other DPP-4 inhibitors (namely sitagliptin, vildagliptin, saxagliptin, and linagliptin).…”

Spectrophotometric Assay of Teneligliptin in Pharmaceutical Tablet Dosage Form by Ion-Pair Complex Method Using Bromo Phenol Blue (Bpb)

“…Therefore, incretin-related agents such as DPP- Teneligliptin which inhibits the enzyme DPP-4 and degrades incretin, a hormone which adjusts blood glucose level and improves blood glucose control as stated above. A survey of chemical literature has shown that the drug Teneligliptin is effectively used to treat Type 2 diabetes mellitus [1][2][3][4][5][6][7][8] (T2DM). Further it is noticed that only a very few methods on the development and validation for the estimation of Teneligliptin are reported which include UV spectrophotometric methods [9][10] and High Performance Thin Layer Chromatographic (HPTLC) method [11] and High Performance Liquid Chromatography (HPLC) methods.…”

Teneligliptin: Heralding Change in Type 2 Diabetes

“…There were no hypoglycaemic symptoms or serious adverse events. [14] studied the effect of Teneligliptin 20 mg/day as an initial therapy in 31 newly diagnosed type 2 diabetes patients mean age 58.29 ± 14.95 for 3 months. Significant reductions in HbA1c (from 10.34 ± 2.06 to 8.38 ± 2.23%; p < 0.00001) and fasting blood glucose (from 211.3 ± 68.4 to 167.3 ± 70.2 mg/dL; p < 0.0002) levels were observed without any clinically significant adverse events.…”